Venus Medtech (Hangzhou) Inc. (VMTHF)
OTCMKTS
· Delayed Price · Currency is USD
0.2512
-0.0359 (-12.50%)
Apr 23, 2025, 4:00 PM EDT
Venus Medtech (Hangzhou) Revenue
In the year 2024, Venus Medtech (Hangzhou) had annual revenue of 470.83M CNY, down -4.18%. Venus Medtech (Hangzhou) had revenue of 240.11M in the half year ending December 31, 2024, with 22.20% growth.
Revenue
470.83M CNY
Revenue Growth
-4.18%
P/S Ratio
2.24
Revenue / Employee
681.38K CNY
Employees
691
Market Cap
144.37M USD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SS Innovations International | 20.65M |
| Endo Inc. | 1.76B |
| Veradigm | 588.02M |
| Northwest Biotherapeutics | 1.38M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 200.90M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
Venus Medtech (Hangzhou) News
- 3 days ago - Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations - PRNewsWire
- 8 months ago - Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study - PRNewsWire
- 11 months ago - Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S. - PRNewsWire
- 1 year ago - Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval - PRNewsWire
- 1 year ago - Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023 - PRNewsWire